Interpace Biosciences (ID)【IDXG】銘柄情報

Interpace Biosciences Inc (ID) (IDXG) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

1.63

( 1.24% )

買値

1.61

売値

1.65

出来高

1,100

1.61 日の範囲 1.63

0.755 52 週間の範囲 2.40

時価総額

45.152M

前日終値

1.61

始値

1.61

時刻

100

1.63

最終取引時間

財務取引量

US$ 1,782

VWAP

1.62

平均取引量 (3 か月)

US$ 6,839

発行済株式数

27,700,904

配当利回り

PER

1.87

1 株当たり利益 (EPS)

0.86

歳入

36.25M

純利益

23.65M

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for ma... Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. 詳細を表示

セクター

Healthcare

業界

Medical Diagnostics & Screening

ウェブサイト

www.interpace.com

本社

Parsippany, United States

設立

1986

Interpace Biosciences Inc (ID) is listed in the Healthcare sector of the その他OTC with ticker IDXG. The last closing price for Interpace Biosciences (ID) was US$1.61. Over the last year, Interpace Biosciences (ID) shares have traded in a share price range of US$ 0.755 to US$ 2.40.

Interpace Biosciences (ID) currently has 27,700,904 shares in issue. The market capitalisation of Interpace Biosciences (ID) is US$45.15 million. Interpace Biosciences (ID) has a price to earnings ratio (PE ratio) of 1.87.

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Q1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results

Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.06	-3.55029585799	1.69	1.8	1.58	9957	1.63783076	CS
4	-0.0943	-5.46888592472	1.7243	1.8	1.57	6919	1.66727244	CS
12	-0.37	-18.5	2	2.4	1.57	6798	1.88008019	CS
26	0.33	25.3846153846	1.3	2.4	1.03	7874	1.79237682	CS
52	0.875	115.894039735	0.755	2.4	0.755	8494	1.36422766	CS
156	0.53	48.1818181818	1.1	3.54	0.443325	9132	1.4337884	CS
260	-8.57	-84.0196078431	10.2	10.51	0.443325	8162	2.71298734	CS